Riskpilot← Back to searchSign inGet full accessSWEDISH ORPHAN BIOVITRUM A/S
A/SActiveCVR 19179079Sorgenfrivej 17Wholesale of pharmaceutical and medical goods · NACE 4646Est. 19968 employees
Revenue 2024
DKK 20,7M
-7% vs 2023
EBITDA margin
22.1%
+8% vs 2023
Equity ratio
88.9%
Financial strength
Net profit 2024
DKK 4,6M
+9% vs 2023
| Revenue | DKK 20,7M | -7% |
| EBITDA | DKK 4,6M | +8% |
| Net profit | DKK 4,6M | +9% |
| Total assets | DKK 40,7M | +12% |
| Equity | DKK 36,2M | +14% |
| Employees | 8 | — |
Legal name
SWEDISH ORPHAN BIOVITRUM A/S
CVR number
19179079
Legal form
Aktieselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
8. februar 1996
Share capital
DKK 500.000
Employees
8 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af to bestyrelsesmedlemmer i forening eller af den samlede bestyrelse
Company purpose
Selskabets formål er udvikling, markedsføring og salg af lægemidler til behandling af sjældne sygdomme, samt konsulent virksomhed indenfor helse- og sygdomsområdet, samt virksomhed beslægtet hermed.
Address
Sorgenfrivej 17
Phone
+4532966869
Email
Sanne.bjerregaard@sobi.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 39.028 | 32.623 | 23.486 | 22.183 | 20.724 |
| Staff expenses | -33.916 | -28.710 | -19.833 | -17.941 | -16.141 |
| EBITDA | 5.112 | 3.912 | 3.653 | 4.242 | 4.583 |
| Depreciation & amort. | -8 | -16 | -9 | -8 | -8 |
| EBIT | 5.103 | 3.896 | 3.644 | 4.234 | 4.575 |
| Net financials | 430 | 422 | 588 | 1.276 | 1.424 |
| Profit before tax | 5.533 | 4.318 | 4.231 | 5.510 | 5.999 |
| Tax | 1.255 | 969 | 1.058 | 1.323 | 1.428 |
| Net profit | 4.278 | 3.350 | 3.173 | 4.188 | 4.570 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 36.717 | 33.718 | 32.145 | 36.485 | 40.743 |
| Equity | 20.946 | 24.295 | 27.469 | 31.656 | 36.227 |
| Long-term debt | 2.677 | 0 | 0 | 0 | 0 |
| Short-term debt | 13.095 | 9.423 | 4.676 | 4.829 | 4.517 |
| Total debt | 15.771 | 9.423 | 4.676 | 4.829 | 4.517 |
EBITDA margin
22.1%
This company
15.8%
Market median
+40% vs market
20202024
Equity ratio
88.9%
This company
38.2%
Market median
+133% vs market
20202024
Return on equity
12.6%
This company
18.4%
Market median
+32% vs market
20202024
Net profit margin
22.1%
This company
8.1%
Market median
+173% vs market
20202024
Asset turnover
0.51×
This company
1.12×
Market median
-54% vs market
20202024
Debt / equity
0.12×
This company
0.62×
Market median
+81% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
BG Management | Management | 2017 |
SO Founder | Founder | 1996 |
| Former (4) | ||
LS Management | Management | 2002 – 2003 |
GN Management | Management | 2009 – 2017 |
LH Management | Management | 2005 – 2009 |
UB Management | Management | 2003 – 2005 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2018 | |
| Board of Directors | 2020 | |
| Former (15) | ||
| Board of Directors | 2017 – 2019 | |
| Chairman | 2011 – 2011 | |
| Board of Directors | 1996 – 1997 | |
| Board of Directors | 2012 – 2017 | |
| Board of Directors | 2002 – 2005 | |
| Board of Directors | 2011 – 2012 | |
| Chairman | 2014 – 2018 | |
| Chairman | 1996 – 2000 | |
| Board of Directors | 2005 – 2007 | |
| Chairman | 2011 – 2014 | |
| Board of Directors | 1996 – 2002 | |
| Board of Directors | 2019 – 2020 | |
| Board of Directors | 2019 – 2019 | |
| Board of Directors | 2010 – 2011 | |
| Chairman | 2002 – 2010 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100% | 100% | 2010 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of SWEDISH ORPHAN BIOVITRUM A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lena Storm Christensen | Management | 0 companies |
| Gitte Nøhr Ludvig | Management | 0 companies |
| Bjørn Gustaf Östen Berglund | Management | 0 companies |
| Lisbeth Hansen | Management | 0 companies |
| Ulf Blangsted Henriksen | Management | 0 companies |
| Swedish Orphan AB | Founder | 0 companies |
| Karl Henrik Stenqvist | Board of Directors | 0 companies |
| Hege Hellstrøm | Board of Directors | 0 companies |
| Frank Carl Kennet Rooth | Chairman | 0 companies |
| Gunnar Wilhelm Paro | Board of Directors | 0 companies |
| Alan Henry Raffensperger | Board of Directors | 0 companies |
| Pär Gustav Östensjö | Board of Directors | 0 companies |
| Per Anders Edvell | Board of Directors | 0 companies |
| Mats Olof Wallin | Chairman | 0 companies |
| Hans-Erik Almbo | Chairman | 0 companies |
| Janne Antti Laine | Board of Directors | 0 companies |
| Cameron Geoffrey McDonough | Chairman | 0 companies |
| Soufiane Fahmy | Board of Directors | 0 companies |
| Lars Uno Larsson | Board of Directors | 0 companies |
| Philip Alexander Wood | Board of Directors | 0 companies |
| Christian Dreger | Board of Directors | 0 companies |
| Alf Gunnar Martin Nicklasson | Board of Directors | 0 companies |
| Bo Jesper Hansen | Chairman | 0 companies |